“We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth.”,” Royal Bank of Canada’s analyst commented.
SHPG has been the topic of a number of other research reports. Cowen set a $225.00 price target on shares of Shire and gave the stock a buy rating in a report on Friday, January 5th. Zacks Investment Research raised shares of Shire from a sell rating to a hold rating in a report on Friday, October 27th. Cantor Fitzgerald reaffirmed a buy rating and issued a $222.00 price target on shares of Shire in a report on Friday, October 27th. Liberum Capital raised shares of Shire from a hold rating to a buy rating in a report on Tuesday, November 14th. Finally, ValuEngine raised shares of Shire from a hold rating to a buy rating in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $212.50.
Hedge funds have recently modified their holdings of the business. SeaCrest Wealth Management LLC bought a new stake in Shire during the 4th quarter valued at $107,000. BB&T Investment Services Inc. grew its position in shares of Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 786 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Shire during the 3rd quarter valued at $159,000. Benjamin F. Edwards & Company Inc. grew its position in shares of Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 921 shares in the last quarter. Finally, Regal Investment Advisors LLC purchased a new position in shares of Shire during the 4th quarter valued at $209,000. 20.31% of the stock is currently owned by institutional investors and hedge funds.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.